Primary HIV type 1 infection

Clinical Infectious Diseases

Volumn 38, Issue 10, 2004, Pages 1447-1453

  Kassutto, Sigall ^a   Rosenberg, Eric S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EFAVIRENZ; ENZYME INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; PROTEINASE INHIBITOR; VIRUS VACCINE; ZIDOVUDINE;

DECISION MAKING; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; VIREMIA; VIRUS INFECTION;

ANTI-HIV AGENTS; DISEASE PROGRESSION; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; VIREMIA;

EID: 2442653883     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/420745     Document Type: Review

References (34)

1. Geijtenbeek T, van Kooyk Y. DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr Top Microbiol Immunol 2003; 276:31-54.
2. Niu MT, Jermano JA, Reichelderfer P, Schnittman SM. Summary of the National Institutes of Health workshop on primary human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1993; 9:913-24.
3. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection [review]. N Engl J Med 1998; 339:33-9.
4. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997; 3:338-40.
5. Tang J, Shelton B, Makhatadze N, et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002; 76:662-72.
6. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-64 (erratum: Ann Intern Med 1997; 126:174).
7. Schacker T, Hughes JP, Shea T, Coombs R, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-20.
8. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614-22.
9. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605-13.
10. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5.
11. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath J. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-74.
12. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure [review]. Am J Med 1997; 102:117-24 (discussion: 125-6).
13. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to aids in a large cohort of homosexual men. J Infect Dis 2000; 181:872-80.
14. Walensky RP, Rosenberg ES, Ferraro JM, Losina E, Walker BD, Freedberg KA. Investigation of primary human immunodeficiency virus infection in patients who test positive for heterophile antibody. Clin Infect Dis 2001; 33:570-2.
15. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-6.
16. Hecht FM, Busch MP, Rawal BD, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002; 16:1119-29.
17. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280:42-8.
18. Rosenberg ES, Caliendo AM, Walker BD. Acute HIV infection among patients tested for mononucleosis. N Engl J Med 1999; 340:969.
19. Pilcher CD, Eron JJ, Vemazza PL, et al. Sexual transmission during the incubation period of primary HIV infection. JAMA 2001; 286:1713-4.
20. Kinloch-de-Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary HIV infection. N Engl J Med 1995; 333:408-13.
21. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
22. + T lymphocytes. Proc Natl Acad Sci U S A 2000; 97:3382-7.
23. Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181:121-31.
24. Lacabaratz-Porret C, Urrutia A, Doisne JM, et al. Impact of antiretroviral therapy and changes in virus load on HIV-specific T cell responses in primary HIV infection. J Infect Dis 2003; 187:748-57.
25. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193:169-80.
26. Berrey MM, Schacker T, Collier AC, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001; 183:1466-75.
27. British HIV Association guidelines for the treatment of HIV disease with antiretroviral therapy. 2003. Available at: http://www. aidsmap.com/about/bhiva/ bhivagd.asp. Accessed 26 December 2003.
28. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA panel. JAMA 2002; 288:222-35.
29. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 2004. Available at: http://www.aidsinfo.nih.gov. Accessed 26 April 2004.
30. Trotta MP, Ammassari A, Cozzi-Lepri A, et al. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse-transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS 2003; 17:1099-102.
31. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282:1142-9.
32. Katz MH, Gerberding JL. Postexposure treatment of people exposed to HIV through sexual contact or injection-drug use. N Engl J Med 1997; 336:1097-100.
33. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340:1683-4.
34. Montefiori DC, Hill TS, Vo HT, Walker BD, Rosenberg E. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 2001; 75:10200-7.